SPINK7/ECRG2 antibody (C-Term)

Catalog No. ABIN1887135

Product Details anti-SPINK7/ECRG2 Antibody

Target: SPINK7/ECRG2 (SPINK7) (Serine Peptidase Inhibitor, Kazal Type 7 (SPINK7))

Binding Specificity: C-Term

Reactivity: Human, Mouse, Rat

Host: Rabbit

Clonality: Polyclonal

Conjugate: This SPINK7/ECRG2 antibody is un-conjugated

Application: ELISA, Western Blotting (WB)

Cross-Reactivity (Details): ECRG2 antibody is predicted to not cross-react with other ECRG family members

Purification: Affinity chromatography purified via peptide column

Immunogen: 16 amino acid peptide near the carboxy terminus of human ECRG2.

Application Details

Restrictions: For Research Use only

Handling

Format: Liquid

Buffer: PBS containing 0.02 % sodium azide.

Preservative: Sodium azide

Precaution of Use: WARNING: Reagents contain sodium azide. Sodium azide is very toxic if ingested or inhaled. Avoid contact with skin, eyes, or clothing. Wear eye or face protection when handling. If skin or eye contact occurs, wash with copious amounts of water. If ingested or inhaled, contact a physician immediately. Sodium azide yields toxic hydrazoic acid under acidic conditions. Dilute azide-containing compounds in running water before discarding to avoid accumulation of potentially explosive deposits in lead or copper plumbing.

Handling Advice: Avoid freezing and thawing repeatly.

Storage: 4 °C/-20 °C

Storage Comment: Store at 4 °C for short term use.Store at -20 °C for long term preservation.

Target Details for SPINK7/ECRG2

Target: SPINK7/ECRG2 (SPINK7) (Serine Peptidase Inhibitor, Kazal Type 7 (SPINK7))

Alternative Name: ECRG2 (SPINK7 Products)

Synonyms: Ecg2 antibody, Ecrg2 antibody, OM antibody, ECG2 antibody, ECRG2 antibody, EG408198 antibody, serine peptidase inhibitor, Kazal type 7 antibody, serine peptidase inhibitor, Kazal type 7 (putative) antibody, Spink7 antibody, SPIK7 antibody, SPINK7 antibody

Background: The esophageal cancer-susceptibility gene 2 (ECRG2), also known as SPINK7, is a novel tumor suppressor gene identified from the human esophagus.It interacts directly with metallothionein 2A and urokinase-type plasminogen activator (uPA), and downregulates the activity of uPA, leading to reduced cancer cell migration, invasion and metastasis.ECRG2 forms a complex with uPA and its receptor uPAR, modifying the dynamic association of uPAR with beta1 integrins and disrupting the Src/MAP kinase pathway that normally stimulates cell migration and invasion.ECRG2 may thus represent a novel therapeutic target for cancer.
Synonyms: Esophageal cancer-susceptibility gene 2 protein, ECG2, serine protease inhibitor Kazal-type 7, SPINK7